2023 World Conference on Lung Cancer (Posters)-EP07.05. Minimal Residual Lesion Might Predict Adequate Cycles for Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer

EP07.05. Minimal Residual Lesion Might Predict Adequate Cycles for Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

In this study, researchers aimed to assess the optimal number of cycles of pre-surgical anti PD-1 treatment for non-small cell lung cancer (NSCLC) and explore the use of minimal residual lesion (MRD) as a predictive tool for treatment efficacy. The study included stage IIIA NSCLC patients who were negative for EGFR mutation and ALK rearrangement. After two courses of treatment with Sintilimab combined with Platinum-based Chemotherapy, the patients were randomly assigned to either the control group (surgical resection and postoperative treatment for 2 courses) or the experimental group (surgery after 4 courses of treatment). The primary endpoint was the pathological complete regression (pCR) rate.<br /><br />Three patients were monitored for MRD dynamics using ultradeep targeted next-generation sequencing. Two patients in the experimental group showed complete clearance of circulating tumor DNA (ctDNA) post-treatment, indicating a positive response to therapy. In contrast, the patient in the control group showed only a minor change in ctDNA levels. While all three patients were defined as having partial regression according to radiology criteria, the pathological regression analysis revealed that the two patients in the experimental group had a pCR, while the patient in the control group only had 20% tumor regression.<br /><br />The study suggests that 4 cycles of adjuvant immunotherapy may be more beneficial than 2 cycles and highlights the potential of MRD as a predictive tool for neoadjuvant immunotherapy in NSCLC. The researchers propose that MRD could be used to determine the optimal number of neoadjuvant cycles in future treatments. This study contributes to the ongoing efforts to push the boundaries of early-stage NSCLC treatment, specifically in the context of immunotherapy.

Asset Subtitle

Dong Lin

Meta Tag

Speaker Dong Lin

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

pre-surgical anti PD-1 treatment

non-small cell lung cancer

MRD

predictive tool

Sintilimab

Platinum-based Chemotherapy

pathological complete regression

ctDNA

adjuvant immunotherapy

neoadjuvant immunotherapy